In conclusion we have demonstrated that IL-24 exerts its anti-metastatic activity by disrupting the SDF-1/CXCR4 axis and that IL-24-based therapy in conjunction with CXCR4 inhibitors will be more effective in attenuating lung cancer metastasis. This evidence concerns the gene CXCL12 and lung carcinoma.